Two tumours can share the name prostate cancer and behave very differently. Understanding why is one of the field’s most consequential problems.
A prostate cancer DNA study published in Nature on 9 September 2026 approaches that problem by reading the damage accumulated across a tumour’s DNA. The researchers identified eight combined patterns, or mutational footprints, that together explain mutational processes in 85% of the primary prostate cancer genomes examined. Peer-reviewed study
That percentage is easy to misread. It is not an 85% cure rate, a diagnostic accuracy score or evidence that doctors can now predict every patient’s future. It describes how much of the studied genomic landscape the researchers could account for with their framework.
Reading the damage as a history
The international team analysed 959 tumour genomes from men in seven countries. Rather than examining only changes to individual DNA letters, it combined several scales of damage, including small insertions and deletions, rearranged sections and larger gains or losses of genetic material. Spanish National Cancer Research Centre summary
A useful analogy is a damaged manuscript. Misspellings, missing sentences and pages bound in the wrong order can point to different problems in how it was copied. Reading all those clues together can reveal more than counting spelling mistakes alone.
In the tumours, the patterns implicated processes such as disrupted DNA copying and repair, alongside hormone-related activity. Individual cancers often showed a mixture of processes. The eight footprints therefore should not be presented as eight neat boxes into which every patient fits. CNIO explanation
The researchers also found associations with subsequent spread. Four footprints, present in 37% of the primary tumours, were linked to shorter time to metastasis—the spread of cancer beyond its original site. Association is the key word: a pattern linked to risk across a group does not determine what will happen to one person. Study findings
A map that still needs a clinical route
This is research using human tumour samples and clinical information. It is not a trial showing that a new treatment improves survival, and it does not introduce an approved test that replaces existing assessments.
The potential importance lies in a future possibility: a tumour’s combination of damage patterns might help researchers develop more informative markers of risk. A biomarker is a measurable biological feature used to provide information about disease. CNIO describes these findings as a step towards such markers, with clinical application still ahead. CNIO’s assessment
Our interpretation is that the strongest follow-up would test whether this information improves decisions beyond what clinicians already know. A scientifically interesting pattern becomes clinically useful only if it is reliable, practical to measure and changes an outcome that matters.
Researchers would also need to establish where the approach works well and where it fails. A method can perform impressively in the samples used to develop it yet prove less informative in a different population or setting.
The study does not resolve those questions. It offers a more detailed account of the processes that helped shape a cancer—and a clearer set of hypotheses to test. That is a meaningful advance in understanding, even before it becomes something a clinic can use.
Featured image: Representative laboratory research. Photo: Louis Reed / Unsplash.
Leave a Reply